Related references
Note: Only part of the references are listed.Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Timo Rath et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2015)
Population Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein
Ivan Nestorov et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2015)
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu et al.
BLOOD (2014)
Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
S. Lalezari et al.
HAEMOPHILIA (2014)
An objective method for assessing adherence to prophylaxis in adults with severe haemophilia
S. Ho et al.
HAEMOPHILIA (2014)
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial
Pier Mannuccio Mannucci et al.
BLOOD (2013)
Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes
Q. Y. Wang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
R. T. Peters et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
M. J. Manco-Johnson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight
Sven Bjorkman et al.
BLOOD (2012)
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
Jennifer A. Dumont et al.
BLOOD (2012)
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Jerry S. Powell et al.
BLOOD (2012)
Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey
S. Zappa et al.
HAEMOPHILIA (2012)
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
L. A. Valentino et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Up-regulation of platelet activation in hemophilia A
Esther R. van Bladel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
P. W. Collins et al.
HAEMOPHILIA (2011)
Costs of Care in Hemophilia and Possible Implications of Health Care Reform
Kathleen A. Johnson et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Biological Rationale for New Drugs in the Bleeding Disorders Pipeline
Patrick F. Fogarty
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Improvements in factor concentrates
David Lillicrap
CURRENT OPINION IN HEMATOLOGY (2010)
Pharmacokinetic dosing in prophylactic treatment of hemophilia A
M. Carlsson et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance
V. Terraube et al.
HAEMOPHILIA (2010)
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII
M. Recht et al.
HAEMOPHILIA (2009)
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
P. W. Collins et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor
Lisa Gallinaro et al.
BLOOD (2008)
Likelihood based approaches to handling data below the quantification limit using NONMEM VI
Jae Eun Ahn et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma
Koichi Matsuzaki et al.
HEPATOLOGY (2007)
Clearance mechanisms of von Willebrand factor and factor VIII
P. J. Lenting et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A
Magali Bolon-Larger et al.
THERAPEUTIC DRUG MONITORING (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII - an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia
H. Stass
HAEMOPHILIA (2006)
Practice patterns in haemophilia A therapy - global progress towards optimal care
S Geraghty et al.
HAEMOPHILIA (2006)
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia
AD Shapiro et al.
HAEMOPHILIA (2005)
Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods
J Goudemand et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS)
DR Globe et al.
HAEMOPHILIA (2004)
Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective
S Björkman
HAEMOPHILIA (2003)
Barriers to compliance with prophylaxis therapy in haemophilia
MR Hacker et al.
HAEMOPHILIA (2001)
Medical progress - The hemophilias - From royal genes to gene therapy
PM Mannucci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice
CV Denis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
